Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

FDA Approves Oxycontin for Children 11 and Older

By Drug Discovery Trends Editor | August 14, 2015

The Food and Drug Administration on Thursday approved the powerful painkiller OxyContin for a new use in children 11 to 16 who are suffering from severe, long-term pain.
 
OxyContin is an extended-release opioid that has long been used to treat around-the-clock pain in adults. But most pain medications are not approved for use in children.
 
The FDA says it asked drugmaker Purdue Pharma to study how to safely use OxyContin in children.
 
“This program was intended to fill a knowledge gap and provide experienced health care practitioners with the specific information they need to use OxyContin safely in pediatric patients,” Sharon Hertz, an FDA drug division director, wrote in an online post.
 
Under the new approval, doctors are directed to only prescribe OxyContin to children who can already tolerate a minimum dose of 20 milligrams of oxycodone, the drug ingredient in OxyContin. Taking a sudden dose of an opioid can lead to overdose and death if patients haven’t previously been exposed to the drug type.
 
The FDA notes that the Duragesic patch, which releases fentanyl, is the only other opioid approved for children.
 
OxyContin was re-formulated in 2010 to discourage patients from crushing the tablets for snorting or injection. Purdue Pharma discontinued the older version of its blockbuster drug, which was long associated with problems of addiction, overdose and death.
 
The FDA notes that the same health warnings that apply to adults apply to children taking OxyContin. Physicians should not combine the drug with any other medications that can add to its sedating effects, which could lead to breathing difficulties.
 
As a condition of approval, the FDA is requiring Stamford, Connecticut-based Purdue to conduct a follow-up study examining rates of injury, overdose, accidents and medication errors in patients ages 11 to 17. The final study is due April 2019.
 
Doctors prescribe opioids for a wide range of ailments, from post-surgical pain to arthritis and migraines. Medical experts continue to disagree over the appropriate role of the drugs, with some arguing that they should be reserved for the most severe cases, such as cancer pain or end-of-life care.
 
The FDA mentions severe pain due to trauma, surgery or cancer as potential uses for opioids in children.
 
OxyContin was the first in a class of long-acting opioids designed to deliver powerful, around-the-clock pain relief. The pills and tablets are formulated to slowly release their drug contents over 12 or more hours. But abusers often try to get a massive, heroin-like high by releasing the entire dose at once via chewing, snorting or injecting crushed tablets’ contents.
 
Source: Associated Press

Filed Under: Drug Discovery

 

Related Articles Read More >

Sai Life Sciences exec: GLP-1 boom has ‘exploded the peptide field’ as firm opens new center
Novartis in the Pharma 50
Swissmedic approves first malaria treatment for infants
Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE